Predicting disease progression and poor outcomes in patients with moderately active rheumatoid arthritis: a systematic review-Reference-Cited by-同舟云学术

Predicting disease progression and poor outcomes in patients with moderately active rheumatoid arthritis: a systematic review

Published:2019-01-01 Issue:1 Volume:3 Page:
ISSN:2514-1775
Container-title:Rheumatology Advances in Practice
language:en
Short-container-title:

Author:

Edwards Christopher J¹,Kiely Patrick²,Arthanari Subhashini³,Kiri Sandeep⁴,Mount Julie⁵,Barry Jane⁶,Mitchell Catherine R⁷,Field Polly⁷,Conaghan Philip G⁸

Affiliation:

1. NIHR Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton

2. Rheumatology Department, St George’s University Hospital NHS Foundation Trust, London, UK

3. SAMETA (South Asia, Middle East, Turkey and Africa), Eli Lilly (Singapore) Pte Ltd, Singapore

4. Health Outcomes and HTA Department

5. Global Patient Outcomes and Real Word Evidence (GPORWE) International

6. Medical Affairs, Eli Lilly and Company Ltd, Basingstoke

7. Value Demonstration Practice, Oxford PharmaGenesis Ltd, Oxford

8. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK

Funder

Eli Lilly and Company

Publisher

Oxford University Press (OUP)

Subject

Rheumatology

Link

http://academic.oup.com/rheumap/article-pdf/3/1/rkz002/28866122/rkz002.pdf

Reference35 articles.

1. Rheumatoid arthritis—early diagnosis and disease management;Schneider;Dtsch Ärztebl Int,2013

2. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice;Anderson;Arthritis Care Res,2012

3. Identifying patients with rheumatoid arthritis with moderate disease activity at risk of significant radiographic progression despite methotrexate treatment;Fautrel;RMD Open,2015

4. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update;Smolen;Ann Rheum Dis,2017

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnostic accuracy of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in rheumatoid arthritis: a systematic review and meta-analysis;Clinical and Experimental Medicine;2024-09-04

2. Neutrophil‐to‐monocyte ratio is the better new inflammatory marker associated with rheumatoid arthritis activity;Health Science Reports;2023-08

3. Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study;Rheumatology and Therapy;2022-10-09

4. Association of serum hepatoma‐derived growth factor levels with disease activity in rheumatoid arthritis: A pilot study;Journal of Clinical Laboratory Analysis;2022-05-02

5. Analysis of clinical and anamnestic factors affecting endothelial glycocalyx condition in patients with active rheumatoid arthritis;"Arterial’naya Gipertenziya" ("Arterial Hypertension");2022-03-21